Hypertension and Diabetes Mellitus Community Management Center(HAD-COME) Project

Hypertension Clinical Trial

Official title:

Establishment of Hypertension and Diabetes Mellitus Community Management Center(HAD-COME) Project

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04229628
• Other study ID #: 2019364H(R1)
• Status: Recruiting
• Start date: January 1, 2020
• Est. completion date: December 31, 2023

Study information

• Verified date: December 2019
• Source: Guangdong Provincial People's Hospital
• Contact: Feng Ying-qing, PhD
• Phone: +862083827812
• Email: 651792209[@]qq.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To develop and implement quality improvement programs for the treatment and management of hypertension and diabetes,and preventing and controlling hypertension and diabetes-related diseases in Chinese community. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of hypertension and diabetes in Chinese community.

Description:

The aim of this project was to improving care for hypertension and diabetes mellitus in Chinese community. Study population including subjects who are hypertension and/or diabetes mellitus, of any race or ethnicity, any age.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100000
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2020
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• In accordance with the diagnosis of essential hypertension;

• In accordance with the diagnosis of type 2 diabetes mellitus.

Exclusion Criteria:

• Non-type 2 diabetes patients

• Secondary hypertension

• Non-hypertensive patients

• Type 1 diabetes or other types of diabetes

Related Conditions & MeSH terms

• Diabetes Mellitus
• Hypertension

Intervention

Other:
• No special intervention
No special intervention

Locations

Country	Name	City	State
China	Guangdong Provincial People's Hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Guangdong Provincial People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of community hypertension patients receiving treatment as Chinese guideline recommended	Proportion of community hypertension patients receiving treatment as Chinese guideline recommended at the time of enrollment	at the time of enrollment
Primary	Proportion of community diabetes mellitus patients receiving treatment as Chinese guideline recommended	Proportion of community diabetes mellitus patients receiving treatment as Chinese guideline recommended at the time of enrollment	at the time of enrollment